- 3 -

Int'l. Appln. No.: PCT/EP00/05841

Docket No. B45187

Amendments to the Claims

IN THE CLAIMS:

Please cancel claims 1-12.

Please add new claims 13-24.

- 13. A composition for raising an immune response comprising a malaria antigen and an immunostimulatory CpG oligonucleotide.
- 14. A composition as claimed in claim 13 wherein the antigen is selected from the group of malaria antigens consisting of RTS, RTS*, TRAP and immunologically equivalent derivatives thereof.
- 15. A composition as claimed in claim 13 wherein the vaccine comprises TRAP or immunologically equivalent derivative and one of RTS or RTS*.
- 16. A composition as claimed in claim 13 further comprising an aluminum salt, 3 de-O-acylated monophosphoryl lipid A or a saponin adjuvant.
- 17. A composition as claimed in claim 13 wherein the oligonucleotide comprises two CpG dinucleotides.
- 18. A composition as claimed in claim 13 wherein the CpG oligonucleotide is between 15-45 nucleotides in length.
- 19. A composition as claimed in claim 13 wherein the CpG oligonucleotide comprises at least one phosphorothioate internucleotide bond.
- 20. A composition as claimed in claim 13 wherein the oligonucleotide is selected from the group consisting of oligonucleotides designated as WD1001, WD1002, WD1003, WD1004, WD1005, WD1006, and WD1007.

Int'l. Appln. No.: PCT/EP00/05841

Docket No. B45187

- 21. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 13 to a patient.
- 22. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 16 to a patient.
- 23. A method of producing a composition as claimed in claim 13 comprising admixing a malarial antigen and a CpG immunostimulatory oligonucleotide.
- 24. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a CpG oligonucleotide followed after a suitable time by an effective amount of a malaria antigen.